Hamza, S.; Garanina, E.E.; Shkair, L.; Alsaadi, M.; Khaiboullina, S.F.; Tezcan, G.
Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer. Pharmaceuticals 2024, 17, 299.
https://doi.org/10.3390/ph17030299
AMA Style
Hamza S, Garanina EE, Shkair L, Alsaadi M, Khaiboullina SF, Tezcan G.
Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer. Pharmaceuticals. 2024; 17(3):299.
https://doi.org/10.3390/ph17030299
Chicago/Turabian Style
Hamza, Shaimaa, Ekaterina E. Garanina, Layaly Shkair, Mohammad Alsaadi, Svetlana F. Khaiboullina, and Gulcin Tezcan.
2024. "Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer" Pharmaceuticals 17, no. 3: 299.
https://doi.org/10.3390/ph17030299
APA Style
Hamza, S., Garanina, E. E., Shkair, L., Alsaadi, M., Khaiboullina, S. F., & Tezcan, G.
(2024). Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer. Pharmaceuticals, 17(3), 299.
https://doi.org/10.3390/ph17030299